Lumiliximab

From WikiMD.org
(Redirected from Gomiliximab)
Jump to navigation Jump to search

Lumiliximab (pronounced loo-mi-lixi-mab) is a monoclonal antibody designed for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It is a biopharmaceutical product that was developed by Biogen Idec Inc.

Etymology

The name "Lumiliximab" is derived from the Latin word "lumen" meaning light, and "liximab" which is a common suffix for monoclonal antibodies.

Mechanism of Action

Lumiliximab works by binding to a specific protein, CD23, on the surface of B-cells. This binding triggers the immune system to destroy these cells, thereby reducing the number of cancerous cells in the body.

Clinical Trials

Lumiliximab has been tested in several clinical trials. In a Phase II trial, it was combined with fludarabine, cyclophosphamide, and rituximab (FCR) for the treatment of B-CLL. The results showed that the combination of Lumiliximab and FCR was well-tolerated and had a high response rate.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski